Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Drugged Driving in Wisconsin: Oral Fluid Versus Blood.

Edwards LD, Smith KL, Savage T.

J Anal Toxicol. 2017 Jul 1;41(6):523-529. doi: 10.1093/jat/bkx051.

PMID:
28830121
2.

Frequency of influenza H3N2 intra-subtype reassortment: attributes and implications of reassortant spread.

Maljkovic Berry I, Melendrez MC, Li T, Hawksworth AW, Brice GT, Blair PJ, Halsey ES, Williams M, Fernandez S, Yoon IK, Edwards LD, Kuschner R, Lin X, Thomas SJ, Jarman RG.

BMC Biol. 2016 Dec 29;14(1):117. doi: 10.1186/s12915-016-0337-3.

3.

Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD.

Rabinovich RA, Miller BE, Wrobel K, Ranjit K, Williams MC, Drost E, Edwards LD, Lomas DA, Rennard SI, Agustí A, Tal-Singer R, Vestbo J, Wouters EF, John M, van Beek EJ, Murchison JT, Bolton CE, MacNee W, Huang JT; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators.

Eur Respir J. 2016 May;47(5):1365-73. doi: 10.1183/13993003.01824-2015. Epub 2016 Mar 23.

4.

Clinical and prognostic heterogeneity of C and D GOLD groups.

Agustí A, Rennard S, Edwards LD, MacNee W, Wouters E, Miller B, Tal-Singer R, Mullerova H, Celli B; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators.

Eur Respir J. 2015 Jul;46(1):250-4. doi: 10.1183/09031936.00012215. No abstract available.

5.

One-year change in health status and subsequent outcomes in COPD.

Wilke S, Jones PW, Müllerova H, Vestbo J, Tal-Singer R, Franssen FM, Agusti A, Bakke P, Calverley PM, Coxson HO, Crim C, Edwards LD, Lomas DA, MacNee W, Rennard SI, Yates JC, Wouters EF, Spruit MA.

Thorax. 2015 May;70(5):420-5. doi: 10.1136/thoraxjnl-2014-205697. Epub 2015 Mar 17.

6.

Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis.

Rennard SI, Locantore N, Delafont B, Tal-Singer R, Silverman EK, Vestbo J, Miller BE, Bakke P, Celli B, Calverley PM, Coxson H, Crim C, Edwards LD, Lomas DA, MacNee W, Wouters EF, Yates JC, Coca I, Agustí A; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints.

Ann Am Thorac Soc. 2015 Mar;12(3):303-12. doi: 10.1513/AnnalsATS.201403-125OC.

PMID:
25642832
7.

A randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthma.

Lee LA, Briggs A, Edwards LD, Yang S, Pascoe S.

Respir Med. 2015 Jan;109(1):63-73. doi: 10.1016/j.rmed.2014.10.009. Epub 2014 Oct 28.

8.

The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study.

Lee LA, Yang S, Kerwin E, Trivedi R, Edwards LD, Pascoe S.

Respir Med. 2015 Jan;109(1):54-62. doi: 10.1016/j.rmed.2014.09.012. Epub 2014 Oct 2.

9.

Common genetic variants associated with resting oxygenation in chronic obstructive pulmonary disease.

McDonald ML, Cho MH, Sørheim IC, Lutz SM, Castaldi PJ, Lomas DA, Coxson HO, Edwards LD, MacNee W, Vestbo J, Yates JC, Agusti A, Calverley PM, Celli B, Crim C, Rennard SI, Wouters EF, Bakke P, Tal-Singer R, Miller BE, Gulsvik A, Casaburi R, Wells JM, Regan EA, Make BJ, Hokanson JE, Lange C, Crapo JD, Beaty TH, Silverman EK, Hersh CP; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints and COPDGene Investigators.

Am J Respir Cell Mol Biol. 2014 Nov;51(5):678-87. doi: 10.1165/rcmb.2014-0135OC.

10.

Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team.

Vestbo J, Agusti A, Wouters EF, Bakke P, Calverley PM, Celli B, Coxson H, Crim C, Edwards LD, Locantore N, Lomas DA, MacNee W, Miller B, Rennard SI, Silverman EK, Yates JC, Tal-Singer R; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Study Investigators.

Am J Respir Crit Care Med. 2014 May 1;189(9):1022-30. doi: 10.1164/rccm.201311-2006PP.

PMID:
24552242
11.

Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality.

Williams MC, Murchison JT, Edwards LD, Agustí A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Vestbo J, Wouters E, Yates JC, van Beek EJ, Newby DE, MacNee W; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators.

Thorax. 2014 Aug;69(8):718-23. doi: 10.1136/thoraxjnl-2012-203151. Epub 2014 Jan 28.

PMID:
24473329
12.

The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study.

Coxson HO, Dirksen A, Edwards LD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Crim C, Duvoix A, Fauerbach PN, Lomas DA, Macnee W, Mayer RJ, Miller BE, Müller NL, Rennard SI, Silverman EK, Tal-Singer R, Wouters EF, Vestbo J; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators.

Lancet Respir Med. 2013 Apr;1(2):129-36. doi: 10.1016/S2213-2600(13)70006-7. Epub 2013 Feb 1.

PMID:
24429093
13.

Lessons from ECLIPSE: a review of COPD biomarkers.

Faner R, Tal-Singer R, Riley JH, Celli B, Vestbo J, MacNee W, Bakke P, Calverley PM, Coxson H, Crim C, Edwards LD, Locantore N, Lomas DA, Miller BE, Rennard SI, Wouters EF, Yates JC, Silverman EK, Agusti A; ECLIPSE Study Investigators.

Thorax. 2014 Jul;69(7):666-72. doi: 10.1136/thoraxjnl-2013-204778. Epub 2013 Dec 5. Review.

PMID:
24310110
14.

Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease.

Cheng DT, Kim DK, Cockayne DA, Belousov A, Bitter H, Cho MH, Duvoix A, Edwards LD, Lomas DA, Miller BE, Reynaert N, Tal-Singer R, Wouters EF, Agustí A, Fabbri LM, Rames A, Visvanathan S, Rennard SI, Jones P, Parmar H, MacNee W, Wolff G, Silverman EK, Mayer RJ, Pillai SG; TESRA and ECLIPSE Investigators.

Am J Respir Crit Care Med. 2013 Oct 15;188(8):948-57. doi: 10.1164/rccm.201302-0247OC.

PMID:
23947473
15.

Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort.

Miller J, Edwards LD, Agustí A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Vestbo J, Wouters E, Yates JC, Macnee W; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators.

Respir Med. 2013 Sep;107(9):1376-84. doi: 10.1016/j.rmed.2013.05.001. Epub 2013 Jun 19.

16.

Reply: minimal or maximal clinically important difference: using death to define MCID.

Polkey MI, Spruit MA, Wouters E, Edwards LD, Tal-Singer R, Celli B; all authors.

Am J Respir Crit Care Med. 2013 Jun 15;187(12):1392. doi: 10.1164/rccm.201301-0155LE. No abstract available.

PMID:
23767907
17.

Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort.

Agusti A, Edwards LD, Celli B, Macnee W, Calverley PM, Müllerova H, Lomas DA, Wouters E, Bakke P, Rennard S, Crim C, Miller BE, Coxson HO, Yates JC, Tal-Singer R, Vestbo J; ECLIPSE Investigators.

Eur Respir J. 2013 Sep;42(3):636-46. doi: 10.1183/09031936.00195212. Epub 2013 Jun 13.

18.

Impact of emphysema and airway wall thickness on quality of life in smoking-related COPD.

Gietema HA, Edwards LD, Coxson HO, Bakke PS; ECLIPSE Investigators.

Respir Med. 2013 Aug;107(8):1201-9. doi: 10.1016/j.rmed.2013.04.016. Epub 2013 May 25.

19.

CT-measured bone attenuation in patients with chronic obstructive pulmonary disease: relation to clinical features and outcomes.

Romme EA, Murchison JT, Edwards LD, van Beek E Jr, Murchison DM, Rutten EP, Smeenk FW, Williams MC, Wouters EF, MacNee W; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Study Investigators.

J Bone Miner Res. 2013 Jun;28(6):1369-77. doi: 10.1002/jbmr.1873.

20.

Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization.

Polkey MI, Spruit MA, Edwards LD, Watkins ML, Pinto-Plata V, Vestbo J, Calverley PM, Tal-Singer R, Agustí A, Bakke PS, Coxson HO, Lomas DA, MacNee W, Rennard S, Silverman EK, Miller BE, Crim C, Yates J, Wouters EF, Celli B; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Study Investigators.

Am J Respir Crit Care Med. 2013 Feb 15;187(4):382-6. doi: 10.1164/rccm.201209-1596OC. Epub 2012 Dec 21.

PMID:
23262518
21.

Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype.

Agustí A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, Vestbo J, Lomas DA, Calverley PM, Wouters E, Crim C, Yates JC, Silverman EK, Coxson HO, Bakke P, Mayer RJ, Celli B; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators.

PLoS One. 2012;7(5):e37483. doi: 10.1371/journal.pone.0037483. Epub 2012 May 18.

22.

Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease.

Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, Calverley P, Coxson H, Crim C, Edwards LD, Lomas DA, Duvoix A, MacNee W, Rennard S, Silverman E, Vestbo J, Wouters E, Agustí A; ECLIPSE Investigators.

Am J Respir Crit Care Med. 2012 May 15;185(10):1065-72. doi: 10.1164/rccm.201110-1792OC. Epub 2012 Mar 15.

PMID:
22427534
23.

Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study.

Waschki B, Spruit MA, Watz H, Albert PS, Shrikrishna D, Groenen M, Smith C, Man WD, Tal-Singer R, Edwards LD, Calverley PM, Magnussen H, Polkey MI, Wouters EF.

Respir Med. 2012 Apr;106(4):522-30. doi: 10.1016/j.rmed.2011.10.022. Epub 2011 Nov 25.

24.

A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13.

Cho MH, Castaldi PJ, Wan ES, Siedlinski M, Hersh CP, Demeo DL, Himes BE, Sylvia JS, Klanderman BJ, Ziniti JP, Lange C, Litonjua AA, Sparrow D, Regan EA, Make BJ, Hokanson JE, Murray T, Hetmanski JB, Pillai SG, Kong X, Anderson WH, Tal-Singer R, Lomas DA, Coxson HO, Edwards LD, MacNee W, Vestbo J, Yates JC, Agusti A, Calverley PM, Celli B, Crim C, Rennard S, Wouters E, Bakke P, Gulsvik A, Crapo JD, Beaty TH, Silverman EK; ICGN Investigators; ECLIPSE Investigators; COPDGene Investigators.

Hum Mol Genet. 2012 Feb 15;21(4):947-57. doi: 10.1093/hmg/ddr524. Epub 2011 Nov 11.

25.

COPD association and repeatability of blood biomarkers in the ECLIPSE cohort.

Dickens JA, Miller BE, Edwards LD, Silverman EK, Lomas DA, Tal-Singer R; Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigators.

Respir Res. 2011 Nov 4;12:146. doi: 10.1186/1465-9921-12-146.

26.

Changes in forced expiratory volume in 1 second over time in COPD.

Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, MacNee W, Miller BE, Silverman EK, Tal-Singer R, Wouters E, Rennard SI; ECLIPSE Investigators.

N Engl J Med. 2011 Sep 29;365(13):1184-92. doi: 10.1056/NEJMoa1105482. Epub 2011 Sep 26.

27.

Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease.

Spruit MA, Polkey MI, Celli B, Edwards LD, Watkins ML, Pinto-Plata V, Vestbo J, Calverley PM, Tal-Singer R, Agusti A, Coxson HO, Lomas DA, MacNee W, Rennard S, Silverman EK, Crim CC, Yates J, Wouters EF; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators.

J Am Med Dir Assoc. 2012 Mar;13(3):291-7. doi: 10.1016/j.jamda.2011.06.009. Epub 2011 Jul 21.

PMID:
21778120
28.

Evaluation of full-length, cleaved and nitrosylated serum surfactant protein D as biomarkers for COPD.

Duvoix A, Miranda E, Perez J, Sorensen GL, Holmskov U, Trapnell BC, Madsen J, Clark HW, Edwards LD, Miller BE, Tal-Singer RM, Lomas DA.

COPD. 2011 Apr;8(2):79-95. doi: 10.3109/15412555.2011.558542.

PMID:
21495836
29.

Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results.

Crim C, Celli B, Edwards LD, Wouters E, Coxson HO, Tal-Singer R, Calverley PM; ECLIPSE investigators.

Respir Med. 2011 Jul;105(7):1069-78. doi: 10.1016/j.rmed.2011.01.010. Epub 2011 Apr 11.

30.

Quantifying the extent of emphysema: factors associated with radiologists' estimations and quantitative indices of emphysema severity using the ECLIPSE cohort.

Gietema HA, Müller NL, Fauerbach PV, Sharma S, Edwards LD, Camp PG, Coxson HO; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators.

Acad Radiol. 2011 Jun;18(6):661-71. doi: 10.1016/j.acra.2011.01.011. Epub 2011 Mar 9.

PMID:
21393027
31.

Evaluation of exhaled breath condensate pH as a biomarker for COPD.

MacNee W, Rennard SI, Hunt JF, Edwards LD, Miller BE, Locantore NW, Tal-Singer R.

Respir Med. 2011 Jul;105(7):1037-45. doi: 10.1016/j.rmed.2011.02.009. Epub 2011 Mar 4.

32.

Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease.

Sin DD, Miller BE, Duvoix A, Man SF, Zhang X, Silverman EK, Connett JE, Anthonisen NA, Wise RA, Tashkin D, Celli BR, Edwards LD, Locantore N, Macnee W, Tal-Singer R, Lomas DA; ECLIPSE Investigators.

Am J Respir Crit Care Med. 2011 May 1;183(9):1187-92. doi: 10.1164/rccm.201008-1220OC. Epub 2011 Jan 7.

33.

Characterisation of COPD heterogeneity in the ECLIPSE cohort.

Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, MacNee W, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Wouters E, Yates JC, Vestbo J; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators.

Respir Res. 2010 Sep 10;11:122. doi: 10.1186/1465-9921-11-122.

34.

Montelukast added to fluticasone propionate does not alter inflammation or outcomes.

Djukanović R, Wilson SJ, Moore WC, Koenig SM, Laviolette M, Bleecker ER, Davis WB, Doherty DE, Olivenstein R, Israel E, Kavuru MS, Kleerup E, Reilly DS, Yancey SW, Edwards LD, Stauffer JL, Dorinsky PM, Jarjour NN.

Respir Med. 2010 Oct;104(10):1425-35. doi: 10.1016/j.rmed.2010.04.004. Epub 2010 Aug 14.

35.

Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease.

Pillai SG, Kong X, Edwards LD, Cho MH, Anderson WH, Coxson HO, Lomas DA, Silverman EK; ECLIPSE and ICGN Investigators.

Am J Respir Crit Care Med. 2010 Dec 15;182(12):1498-505. doi: 10.1164/rccm.201002-0151OC. Epub 2010 Jul 23.

36.

Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort.

Spruit MA, Watkins ML, Edwards LD, Vestbo J, Calverley PM, Pinto-Plata V, Celli BR, Tal-Singer R, Wouters EF; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators.

Respir Med. 2010 Jun;104(6):849-57. doi: 10.1016/j.rmed.2009.12.007. Epub 2010 May 14.

37.

Acute and chronic lung function responses to salmeterol and salmeterol plus fluticasone propionate in relation to Arg16Gly beta(2)-adrenergic polymorphisms.

Yancey SW, Klotsman M, Ortega HG, Edwards LD, Anderson WH.

Curr Med Res Opin. 2009 Apr;25(4):1011-8. doi: 10.1185/03007990902805981 .

PMID:
19275519
38.

Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD.

Lomas DA, Silverman EK, Edwards LD, Locantore NW, Miller BE, Horstman DH, Tal-Singer R; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study investigators.

Eur Respir J. 2009 Jul;34(1):95-102. doi: 10.1183/09031936.00156508. Epub 2009 Jan 22.

39.

Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort.

Lomas DA, Silverman EK, Edwards LD, Miller BE, Coxson HO, Tal-Singer R; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators.

Thorax. 2008 Dec;63(12):1058-63. doi: 10.1136/thx.2008.102574. Epub 2008 Aug 29.

PMID:
18757456
40.

Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma.

Bleecker ER, Yancey SW, Baitinger LA, Edwards LD, Klotsman M, Anderson WH, Dorinsky PM.

J Allergy Clin Immunol. 2006 Oct;118(4):809-16. Epub 2006 Aug 28.

PMID:
17030231
41.

Control of airway inflammation maintained at a lower steroid dose with 100/50 microg of fluticasone propionate/salmeterol.

Jarjour NN, Wilson SJ, Koenig SM, Laviolette M, Moore WC, Davis WB, Doherty DE, Hamid Q, Israel E, Kavuru MS, Ramsdell JW, Tashkin DP, Reilly DS, Yancey SW, Edwards LD, Stauffer JL, Dorinsky PM, Djukanovic R.

J Allergy Clin Immunol. 2006 Jul;118(1):44-52. Epub 2006 Jun 2.

PMID:
16815137
42.

Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma.

Ostrom NK, Decotiis BA, Lincourt WR, Edwards LD, Hanson KM, Carranza Rosenzweig JR, Crim C.

J Pediatr. 2005 Aug;147(2):213-20.

PMID:
16126052
43.

Patient perceptions of an inhaled asthma medication administered as an inhalation powder via the Diskus or as an inhalation aerosol via a metered-dose inhaler.

Sheth K, Bernstein JA, Lincourt WR, Merchant KK, Edwards LD, Crim CC, Dorinsky PM.

Ann Allergy Asthma Immunol. 2003 Jul;91(1):55-60.

PMID:
12877450
44.
45.

Efficacy and safety of low-dose fluticasone propionate compared with zafirlukast in patients with persistent asthma.

Brabson JH, Clifford D, Kerwin E, Raphael G, Pepsin PJ, Edwards LD, Srebro S, Rickard K.

Am J Med. 2002 Jul;113(1):15-21.

PMID:
12106618
46.

Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of age.

Creticos P, Knobil K, Edwards LD, Rickard KA, Dorinsky P.

Ann Allergy Asthma Immunol. 2002 Apr;88(4):401-9.

PMID:
11991558
47.
48.

Use of changes in symptoms to predict changes in lung function in assessing the response to asthma therapy.

Dorinsky PM, Edwards LD, Yancey SW, Rickard KA.

Clin Ther. 2001 May;23(5):701-14.

PMID:
11394729
49.

Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma.

Baraniuk J, Murray JJ, Nathan RA, Berger WE, Johnson M, Edwards LD, Srebro S, Rickard KA.

Chest. 1999 Sep;116(3):625-32.

PMID:
10492263
50.

Symbolic interactionism: a framework for the care of parents of preterm infants.

Edwards LD, Saunders RB.

J Pediatr Nurs. 1990 Apr;5(2):123-8.

PMID:
2324927

Supplemental Content

Loading ...
Support Center